PCN132 - Cost-Effectiveness of Vemurafenib as a First-Line Treatment in Patients with Braf V600 Mutation-Positive Unresectable or Metastatic Melanoma in Spain
| Autor: | Rubio-Terrés, C, Orofino, J, Armas, J, Parra, J, Rubio-Rodríguez, D, Grau, S |
|---|---|
| Zdroj: | In Value in Health November 2015 18(7):A453-A453 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect